Nektar Therapeutics

Nektar Therapeutics

Nektar Therapeutics

Nektar is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates designed to improve the benefits of drugs for patients.
Founded
1990
Raised
$45M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$20,000,000
Post-IPO equity - 2016
$25,000,000
Venture capital - 2013
AstraZeneca
Team Size
500+
Employees
$20,000,000 Post-IPO equity
Xconomy

Nektar Therapeutics Gets $20M in Daiichi Deal For Breast Cancer Drug

Health
The Motley Fool

Why Nektar Therapeutics Inc Is Dropping Today

The Motley Fool

Here's Why Nektar Therapeutics Inc. Rose 19% in March

The Motley Fool

Why Nektar Therapeutics Skyrocketed 30% Higher in October --

Stock markets Health